Form 4: Karyopharm Therapeutics Director Deepika Pakianathan Sells Shares
SEC Form 4
Director Deepika Pakianathan reports selling Karyopharm Therapeutics (KPTI) shares in multiple transactions between June 5th and June 7th, 2024.
Summary
- Deepika Pakianathan, a director of Karyopharm Therapeutics, sold shares of common stock between June 5th and June 7th, 2024.
- The sales were executed in multiple transactions at varying prices.
- On June 5th, shares were sold at a weighted average price of $0.9582.
- On June 6th, shares were sold at a weighted average price of $0.9828.
- On June 7th, shares were sold at a weighted average price of $0.9507.
- The shares sold were held directly, with remaining shares held indirectly through Delphi Ventures VIII, L.P. and Delphi BioInvestments VIII, L.P.
- Pakianathan disclaims beneficial ownership of the indirectly held securities except to the extent of her proportionate pecuniary interest.
Sentiment
Score: 4
Explanation: The sentiment is slightly negative due to the director selling shares, which could raise concerns about the company's prospects. However, the director retains indirect ownership, mitigating some of the negative sentiment.
Negatives
- A director selling shares could be interpreted negatively by the market.
Risks
- The sale of shares by a director could indicate a lack of confidence in the company's future prospects, potentially impacting investor sentiment.
Industry Context
Director share sales are a common occurrence in publicly traded companies. The impact on the stock price depends on the size of the sale, the director's position, and the overall market sentiment.
Comparison to Industry Standards
- Comparing these transactions to similar insider sales at comparable biotech companies would require analyzing the size of the transactions relative to the director's holdings and the company's market capitalization.
- For example, if a director at a similarly sized company like Exelixis (EXEL) or Incyte (INCY) sold a comparable percentage of their holdings, it could be viewed in a similar light.
Stakeholder Impact
- Shareholders may react to the news of the director's share sales.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of first reported transaction: Sale of common stock. |
| 06/06/2024 | Date of second reported transaction: Sale of common stock. |
| 06/07/2024 | Date of third reported transaction: Sale of common stock and date of signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.